Helix BioMedix, a biopharmaceutical company specializing in peptides, has promoted of Robin L. Carmichael to president. She will retain her title of chief operating officer and continue as a member of the company’s board of directors. Carmichael will be responsible for all aspects of management of Helix BioMedix, including sales, marketing, business development, pharmaceutical, consumer product programs, skincare brands, research and development, and licensing. R. Stephen Beatty who had been serving as president and chief executive officer, will continue to serve as CEO and has been appointed as chairman of the board of directors. “Due to her strong understanding of our business, Carmichael’s responsibilities have continued to expand since she was recruited in 2007,” says Beatty. “She has played a key role in our continued progress, especially in our licensing efforts. In addition, she has been growing our strategic programs with financial discipline while expanding R&D innovation. I am confident that she will continue to excel in her new position.” In addition to launching major product lines, her past experience includes sales management and marketing positions of increasing responsibility in the life science and medical device industries including six years at Baxter Healthcare.
For more information, www.helixbiomedix.com.